In the field of biologic quality control, Low Endotoxin Recovery (LER) has become an unavoidable challenge. It is not an occasional technical issue, but a multi-dimensional risk control concern covering formulation components, analytical methods, regulatory requirements and medication safety. Based on FDA guidance and PDA Technical Report No. 82 (TR-82), this article interprets the nature of LER, regulatory expectations and practical LER implementation approaches from an industrial technical perspective.

01 Regulatory Background of LER: FDA Guidance and Regulatory Logic

While the FDA has not issued a standalone guidance document exclusively titled "LER Guidance", it has incorporated masking of endotoxins, endotoxin stability, spike recovery and hold-time studies into regulatory expectations across multiple biologic regulatory documents.

In 2012, the FDA released Guidance for Industry: Pyrogens and Endotoxins Testing — Questions and Answers, which explicitly addresses acceptance criteria for endotoxin testing and assay stability testing. A section within this Q&A guidance highlights the criticality of sample storage, handling and hold times:

“Firms should establish procedures for storing and handling (which includes product mixing) samples for bacterial endotoxins analysis using laboratory data that demonstrate the stability of assayable endotoxins content.” “Sampling plan … should consider the potential … impact of in-process hold times.”

For FDA-approved applications where formulations contain known masking agents (e.g., polysorbates, EDTA, citrate buffer systems), reviewers focus heavily on evaluation of endotoxin masking, corresponding mitigation strategies, and submission of spike recovery over time data. Insufficient supporting data may trigger supplementary data requests, extended review timelines, or post-approval commitments (PAC/PMC). Excerpts from FDA BLA review correspondence are listed below:

• FDA BLA Review Letter / Administrative Correspondence — Janssen Biotech, Siltuximab (BLA 125496):

“The effect of hold time on endotoxin recovery should be assessed by spiking a known amount of endotoxin into undiluted drug substance and drug product and then testing for recoverable endotoxin over time. The studies should be conducted using containers of similar composition as those used for drug substance and drug product during hold.”

• FDA BLA Letter (BLA 761085):

“Evaluate the effect of hold time on endotoxin detection by spiking a known amount of standard endotoxin (RSE or purified CSE) into undiluted DP and test for recoverable endotoxin over time.”

• FDA Letter for BLA 761430 (2024):

“Perform a supplemental low endotoxin recovery (LER) study to... examine the effects of hold time on endotoxin recovery... spiked with Reference Standard Endotoxin (RSE)… investigate additional endotoxin detection methods if LER is shown.”

The FDA’s regulatory logic can be summarized as follows: complex formulations, particularly biologics, require a risk-based approach to evaluate the robustness of endotoxin testing, rather than sole reliance on one-time LAL method suitability testing. In short, the FDA expects applicants to provide sustained scientific evidence demonstrating reliable analytical performance under dynamic conditions (storage, preservation, dilution, component interactions, etc.).

LER is no longer merely a laboratory technical or academic topic; it has become a formal regulatory expectation. During BLA reviews, if formulations contain chelating agents, surfactants or similar components, reviewers commonly request hold-time studies or spike recovery data to validate reliable test performance in actual sample matrices.

Accordingly, LER directly impacts approval success and patient safety. Failure to integrate LER risk into release control systems and validation plans may result in delayed reviews or review deficiency inquiries (RFIs).

02 Core Highlights of PDA Technical Report No. 82 (TR-82)

To address industry-wide demand for LER risk management, PDA released Technical Report No. 82 in 2019, systematically organizing the mechanisms underlying LER, recommended hold-time study designs, and multiple mitigation strategies. Key takeaways from TR-82 are outlined below:

（1）Terminology and Definitions

TR-82 provides standardized definitions and practical interpretations for LER, masking, demasking, spike recovery and hold time to align industry-wide comprehension of LER.

（2）Design Principles for LER Hold-Time Studies

① Recommended time point selection: T0 (immediate testing), multi-day hold intervals (e.g., Day 1 / Day 3 / Day 7 / Day 14, etc.)

② Supports two study design formats: chronological spiking approach and reverse-spike method

③ Mandates consideration of sample container type, temperature conditions, storage media, and well-characterized endotoxin standards (RSE or CSE) for spiking

④ Clarifies that hold-time studies are not mandatory components of USP method suitability verification, yet are increasingly requested by regulators as supplementary data for BLA submissions

（3）LER Mechanisms and Contributing Factors

① TR-82 elaborates on root causes of LER, including chelating agents, buffer pH, ionic strength, temperature, hold duration, container adsorption, surfactants, protein-LPS binding, and more

② The report notes variable susceptibility across endotoxin sources, prohibiting exclusive reliance on single endotoxin standards (e.g., NOE). Pharmacopoeia-accepted standards (RSE/CSE) are required to ensure cross-system comparability and regulatory acceptability.

（4）Mitigation / Demasking Strategies

Appendices of TR-82 include case studies covering sample pretreatment demasking techniques (dispersant addition, dilution, sample preprocessing) and alternative detection platforms such as MAT and rFC to resolve masking effects.

（5）Risk Management and Regulatory Trends

TR-82 encourages enterprises to embed LER management into lifecycle risk assessment and control, integrating hold-time characterization and demasking method optimization into lifecycle verification activities.

03 Practical Recommendations for LER Risk Control

Combining FDA guidance, PDA TR-82 frameworks and real-world regulatory submission case studies, a complete framework for LER risk assessment, hold-time study planning and demasking method optimization has been established, serving as a critical bridge linking industrial technical practices and regulatory compliance.

To date, no universal standard method fully eliminates LER phenomena, which is the primary rationale behind the absence of a standalone FDA LER guidance document. The following actionable recommendations apply to LER testing:

• Validation Planning Phase

Integrate LER risks into formal risk assessments and explicitly outline hold-time study schedules within validation protocols (e.g., 0 h, 24 h, 48 h, 72 h, 7 d or longer intervals). For formulations containing high-risk excipients (chelators such as EDTA/citrate buffers, polysorbate surfactants, high-protein matrices including carrier proteins), design parallel test groups with targeted demasking pretreatment for comparative evaluation.

• Execution of Spike Recovery & Hold-Time Studies

Utilize pharmacopoeia-recognized endotoxin standards (RSE or CSE) to conduct spike-and-recovery testing across sequential time points. Forward or reverse spiking designs may be adopted based on timeline and resource constraints. Evaluate confounding variables including container material and storage temperature (ambient, refrigerated, simulated production conditions) on recovery rates.

• Optimization of Demasking Protocols in Case of Significant Recovery Loss

If recoveries fall below pre-defined acceptance thresholds (e.g., 50% or internal specifications), assess demasking interventions including sample pretreatment, metal ion supplementation, dilution, dispersant addition, or commercial demasking kits/reagents supplied by  HZSKBIO^Ⓡ. Validate optimized pretreatment workflows, incorporate them into standard operating procedures (SOPs), and continuously monitor recovery performance across subsequent production batches and stability samples via lifecycle verification or periodic reviews.

• Proactive Lifecycle-Wide LER Risk Management

LER evaluation should not be limited to final drug products; extend hold-time characterization and demasking validation to in-process intermediates, storage, sampling and transportation/refrigeration workflows. Establish in-process control monitoring points for formulation stages with high-risk excipients (high surfactant/buffer/protein loads), and conduct routine spike recovery testing on process samples.

• Alignment with Regulatory Submission Workflows

For global registrations (FDA, EMA etc.), fully disclose LER hold-time study design, demasking method development processes and test results within CMC supporting documentation for clinical or commercial license applications. Comprehensive data packages build regulatory confidence and reduce RFI risk.

04 Conclusion

LER has evolved from an academic observation into a core focus of biologic quality control and regulatory review. By aligning FDA regulatory logic with the technical framework laid out in PDA TR-82, enterprises can implement a full-spectrum control system spanning risk identification, validation design (hold-time & spike recovery), reagent/method optimization (demasking), and lifecycle-wide production monitoring. Proactive LER management is not only a requirement for product safety and regulatory compliance, but also a driver of mature quality systems and streamlined global registration workflows.

All QC, method validation and QA teams should embed LER governance into institutional frameworks, continuously underpin analytical system robustness and compliance with scientific data, and accumulate comprehensive datasets to support the development of universal standardized protocols for LER mitigation.

05 Pyrogen Testing Product Line of HZSKBIO^Ⓡ

• MAT Test Kit: Simultaneous detection of endotoxin and non-endotoxin pyrogens

• Recombinant Cascade Reagent (rCR): Minimizes G-factor false positives and mitigates LER interference

• Kinetic Turbidimetric LAL Reagent: Quantitative detection for in-process production monitoring

• Gel-Clot LAL Reagent: Qualitative testing with rapid, straightforward workflows